المؤلفون: Méndez Vidal Mj, Torres Borrego J, Peña Rosa Mj, Beaudoin Perron A, García Martínez E

المصدر: Anales de Pediatría, Vol 61, Iss 1, Pp 69-73 (2004)

مصطلحات موضوعية: Thorax, medicine.medical_specialty, Spontaneous regression, business.industry, Incidence (epidemiology), Histology, Pericardial Mesothelioma, Clinical manifestation, medicine.disease, Pericardial effusion, Pediatrics, RJ1-570, Pediatrics, Perinatology and Child Health, medicine, Pericardial tumours, Radiology, Teratomas, Differential diagnosis, business, Cardiac Tumors

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6989b8f27f25801a193fb034780456a
http://www.sciencedirect.com/science/article/pii/S1695403304783563

المؤلفون: Joan Carles, Teresa Alonso-Gordoa, Begoña Mellado, María J. Méndez-Vidal, Sergio Vázquez, Aránzazu González-del-Alba, Josep M. Piulats, Pablo Borrega, Enrique Gallardo, Rafael Morales-Barrera, Pilar Paredes, Oscar Reig, Carmen Garcías de España, Ricardo Collado, Teresa Bonfill, Cristina Suárez, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Garde

المساهمون: Institut Català de la Salut, [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Alonso-Gordoa T] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Mellado B] Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Méndez-Vidal MJ] Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain. Reina Sofía University Hospital (HURS), Córdoba, Spain. [Vázquez S] Lucus Augusti University Hospital, Lugo, Spain. [González-del-Alba A] Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain. [Morales-Barrera R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Male, Cancer Research, Antiandrògens - Ús terapèutic, Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists [CHEMICALS AND DRUGS], Abiraterone Acetate, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Androgen Antagonists, Bone Neoplasms, Pròstata - Càncer - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant [DISEASES], Prostatic Neoplasms, Castration-Resistant, hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos [COMPUESTOS QUÍMICOS Y DROGAS], Oncology, Receptors, Androgen, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES], Benzamides, Nitriles, Phenylthiohydantoin, Avaluació de resultats (Assistència sanitària), Humans, Radium

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9578fe4d02c1c74477e8b12ba44cee24
https://doi.org/10.1016/j.ejca.2022.06.057

المؤلفون: Climent MÁ; Valencian Institute of Oncology, Valencia, Spain., Álvarez C; Hospital Universitario Central de Asturias, Oviedo, Spain., Morales R; Vall d'Hebron University Hospital, Barcelona, Spain., Maroto P; Hospital Universitari de La Santa Creu I Sant Pau, Barcelona, Spain., Rodríguez-Vida A; Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Méndez-Vidal MJ; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital (HURS), Cordoba, Spain., Del Muro XG; Catalan Institute of Oncology, Barcelona, Spain., Puente J; Hospital Universitario Clínico San Carlos, Madrid, Spain., Láinez N; University Hospital of Navarra, Pamplona, Spain., Vázquez S; Hospital Universitario Lucus Augusti, Lugo, Spain., Castellano D; Hospital 12 de Octubre, Madrid, Spain., Lang CG; Merck S.L.U., an Affiliate of Merck KGaA, Madrid, Spain., Wang J; Pfizer, Cambridge, MA, USA., di Pietro A; Pfizer Srl, Milan, Italy., Davis C; Pfizer Translational Oncology, La Jolla, CA, USA., Sanz-Castillo B; Pfizer Oncology, Madrid, Spain., Bolós MV; Pfizer Oncology, Madrid, Spain., Valderrama BP; Virgen del Rocío University Hospital, Seville, Spain. bpvalderrama@gmail.com.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jun; Vol. 26 (6), pp. 1532-1538. Date of Electronic Publication: 2023 Dec 15.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: B7-H1 Antigen*/metabolism , Antibodies, Monoclonal, Humanized*/therapeutic use , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/metabolism , Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/mortality , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/metabolism , Carcinoma, Transitional Cell*/pathology, Humans ; Progression-Free Survival ; Female ; Male ; Antineoplastic Agents, Immunological/therapeutic use ; Aged ; Middle Aged ; Maintenance Chemotherapy ; Survival Rate

المؤلفون: Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY., Porta C; University of Bari 'A. Moro,' Bari, Italy.; University of Pavia, Pavia, Italy., Eto M; Kyushu University, Fukuoka, Japan., Powles T; The Royal Free NHS Trust, London, United Kingdom., Grünwald V; University Hospital Essen, Essen, Germany., Hutson TE; Texas Oncology, Dallas, TX., Alekseev B; P.A. Herzen Moscow Oncological Research Institute, Moscow, Russia., Rha SY; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Merchan J; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Goh JC; ICON Research, South Brisbane & Queensland University of Technology, Brisbane, Queensland, Australia., Lalani AA; Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Melichar B; Palacky University, and University Hospital Olomouc, Olomouc, Czech Republic., Hong SH; Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Gurney H; Macquarie University, Sydney, NSW, Australia., Méndez-Vidal MJ; Maimonides Institute for Biomedical research of Cordoba (IMIBIC) Hospital Universitario Reina Sofía, Medical Oncology Department, Córdoba, Spain., Kopyltsov E; State Institution of Healthcare 'Regional Clinical Oncology Dispensary,' Omsk, Russia., Tjulandin S; N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia., Gordoa TA; Hospital Universitario Ramón y Cajal, Madrid, Spain., Kozlov V; State budgetary Health Care Institution 'Novosibirsk Regional Clinical Oncology Dispensary,' Novosibirsk, Russia., Alyasova A; Prevoljskiy Region Medical Centre, Novgorod, Russia., Winquist E; Western University, London, Ontario, Canada., Maroto P; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Kim M; Seoul National University Hospital, Seoul, South Korea., Peer A; Rambam Health Care Campus, Haifa, Israel., Procopio G; Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy., Takagi T; Tokyo Women's Medical University, Tokyo, Japan., Wong S; Western Health, Melbourne, Victoria, Australia., Bedke J; Department of Urology and Transplantation Surgery, Klinikum Stuttgart, Stuttgart, Germany., Schmidinger M; Department of Urology, Medical University of Vienna, Vienna, Austria., Rodriguez-Lopez K; Merck & Co, Inc, Rahway, NJ., Burgents J; Merck & Co, Inc, Kenilworth, NJ., He C; Eisai Inc, Nutley, NJ., Okpara CE; Eisai Ltd, Hatfield, UK., McKenzie J; Eisai Inc, Nutley, NJ., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA.

مؤلفون مشاركون: CLEAR Trial Investigators

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 10; Vol. 42 (11), pp. 1222-1228. Date of Electronic Publication: 2024 Jan 16.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology , Phenylurea Compounds* , Quinolines* , Antibodies, Monoclonal, Humanized*, Humans ; Sunitinib/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Survival Analysis

المؤلفون: Grünwald V; Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Hutson TE; Medical Oncology, Texas Oncology, Dallas, TX, United States., Méndez-Vidal MJ; Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain., Hong SH; Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Winquist E; Department of Oncology, University of Western Ontario, London, ON, Canada., Goh JC; ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia., Maroto P; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Buchler T; Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States., Perini R; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States., He C; Biostatistics, Eisai Inc., Nutley, NJ, United States., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, United Kingdom., McKenzie J; Clinical Research, Eisai Inc., Nutley, NJ, United States., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

المصدر: Frontiers in oncology [Front Oncol] 2024 Mar 01; Vol. 13, pp. 1343027. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2023).

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Méndez-Vidal MJ; Medical Oncology Department, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain. mariajose.mendezvidal@gmail.com., Lázaro Quintela M; Medical Oncology Department, Hospital Alvaro Cunqueiro-Complejo Hospitalario Universitario de Vigo, Pontevedra, Spain., Lainez-Milagro N; Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain., Perez-Valderrama B; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Suárez Rodriguez C; Medical Oncology Department, Hospital Universitario Vall D'Hebron, Barcelona, Spain., Arranz Arija JÁ; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Peláez Fernández I; Medical Oncology Department, Hospital de Cabueñes, Gijón, Spain., Gallardo Díaz E; Medical Oncology Department, Corporació Sanitària Parc Taulì, Barcelona, Spain., Lambea Sorrosal J; Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., González-Del-Alba A; Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Sep; Vol. 25 (9), pp. 2732-2748. Date of Electronic Publication: 2023 Aug 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/therapy , Carcinoma, Renal Cell*/drug therapy , Kidney Neoplasms*/therapy , Kidney Neoplasms*/drug therapy, Male ; Humans ; Female ; Sunitinib/adverse effects ; Nivolumab/therapeutic use ; Quality of Life ; Tyrosine/therapeutic use

المؤلفون: Grünwald V; Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany., Powles T; Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia., Rha SY; Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Porta C; Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Hutson TE; Medical Oncology, Texas Oncology, Dallas, TX, United States., Méndez-Vidal MJ; Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain., Hong SH; Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea., Winquist E; Department of Oncology, University of Western Ontario, London, ON, Canada., Goh JC; ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia., Maroto P; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Buchler T; Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia., Takagi T; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan., Burgents JE; Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States., Perini R; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States., He C; Biostatistics, Eisai Inc., Nutley, NJ, United States., Okpara CE; Clinical Research, Eisai Ltd., Hatfield, United Kingdom., McKenzie J; Clinical Research, Eisai Inc., Nutley, NJ, United States., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

المصدر: Frontiers in oncology [Front Oncol] 2023 Aug 16; Vol. 13, pp. 1223282. Date of Electronic Publication: 2023 Aug 16 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: de Velasco G; Department of Medical Oncology, Madrid, Spain. Electronic address: Gdvelasco.gdv@gmail.com., Alonso-Gordoa T; Department of Medical Oncology and Department of Genitourinary, Germ cell and Endocrine Tumors, Ramón y Cajal University Hospital and Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain., Rodríguez-Vida A; Department of Medical Oncology, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Anguera G; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Campayo M; Department of Medical Oncology, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Pinto Á; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Ortega EM; Department of Medical Oncology, University Hospital of Jaén, Jaén, Spain., Gallardo E; Department of Medical Oncology, University Hospital Parc Taulí, Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain., Núñez NF; Department of Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain., García-Carbonero I; Department of Medical Oncology, University Hospital of Toledo, Toledo, Spain., Reig O; Department of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Barcelona, Spain., Méndez-Vidal MJ; Department of Medical Oncology, University Hospital Reina Sofía, Maimónides Institute for Biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Fernández-Calvo O; Department of Medical Oncology, University Hospital of Ourense, Ourense, Spain., Cassinello NV; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Torregrosa D; Department of Medical Oncology, University Hospital Dr. Peset, Valencia, Spain., López-Martín A; Medical Oncology Department, University Hospital Severo Ochoa, Madrid, Spain., Rosero A; Department of Medical Oncology, University Hospital Infanta Cristina, Parla, Madrid, Spain., Valiente PG; Department of Medical Oncology, University Hospital Marqués de Valdecilla, Santander, Spain., de España CG; Department of Medical Oncology, University Hospital Son Espases, Palma de Mallorca, Spain., Climent MA; Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Santasusana MD; Department of Medical Oncology, Hospital Althaia, Manresa, Spain., Sánchez ÁR; Department of Medical Oncology, University Hospital of León, León, Spain., González IC; Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain., Afonso R; Department of Medical Oncology, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., García Del Muro X; Genitourinary Cancer and Sarcoma Unit, Institut Català d'Oncologia, Hospitalet, Barcelona, Spain., Casinello J; Department of Medical Oncology, University Hospital of Guadalajara, Guadalajara, Spain., Fernández-Parra EM; Department of Medical Oncology, University Hospital Valme, Sevilla, Spain., García Sánchez L; Department of Medical Oncology, University Hospital of Segovia, Segovia, Spain., Afonso J; Department of Medical Oncology, University Hospital of Ferrol, A Coruña, Spain., Polo SH; Department of Medical Oncology, University Hospital Fundación Alcorcón, Madrid, Spain., Asensio Ú; Medical Department, Pfizer Oncology, Madrid, Spain.

المصدر: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Jun; Vol. 21 (3), pp. e166-e174. Date of Electronic Publication: 2022 Dec 05.

نوع المنشور: Observational Study; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/secondary , Antineoplastic Agents*/therapeutic use , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Humans ; Middle Aged ; Sunitinib/therapeutic use ; Retrospective Studies ; Indoles/therapeutic use ; Pyrroles/therapeutic use

المؤلفون: Fernandez-Perez MP; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain., Perez-Navarro E; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain., Alonso-Gordoa T; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Conteduca V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 'Dino Amadori' IRCCS, Meldola, Italy., Font A; Department of Medical Oncology, Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (BARGO), Badalona, Spain., Vázquez-Estévez S; Department of Medical Oncology, H. Universitario Lucus Augusti, Lugo, Spain., González-Del-Alba A; Department of Medical Oncology, H.U. Son Espases, Palma de Mallorca, Spain., Wetterskog D; University College London Cancer Institute, Paul O'Gorman Building, London, UK., Antonarakis ES; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mellado B; Department of Medical Oncology, IDIBAPS, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain., Fernandez-Calvo O; Department of Medical Oncology, Complejo Hospitalario Universitario Ourense, Orense, Spain., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía (HURS), Maimonides Institute for biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Climent MA; Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain., Duran I; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain., Gallardo E; Department of Medical Oncology, Servicio de Oncología Médica, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain., Rodriguez Sanchez A; Department of Medical Oncology, Hospital Universitario de León, León, Spain., Santander C; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain., Sáez MI; Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain., Puente J; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Tudela J; Department of Pathology, Hospital Morales Meseguer, Murcia, Spain., Martínez A; Biobanco de la región de Murcia, IMIB, Nodo 3, Murcia, Spain., López-Andreo MJ; Department of Molecular Biology, SAI-IMIB-Universidad de Murcia, Murcia, Spain., Padilla J; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain., Lozano R; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.; Genitourinary Translational Research Group, Instituto de Investigación Biomédica de Málaga, Málaga, Spain., Hervas D; Data Science Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain., Luo J; Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., de Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 'Dino Amadori' IRCCS, Meldola, Italy., Castellano D; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain., Attard G; University College London Cancer Institute, Paul O'Gorman Building, London, UK., Grande E; MD Anderson Cancer Center Madrid, Madrid, Spain., Gonzalez-Billalabeitia E; Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, IMIB, Murcia, Spain.; Department of Medical Oncology, Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain.; Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain.

المصدر: The Prostate [Prostate] 2023 Mar; Vol. 83 (4), pp. 376-384. Date of Electronic Publication: 2022 Dec 23.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE

مواضيع طبية MeSH: Neoplastic Cells, Circulating*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology, Humans ; Male ; Biomarkers, Tumor/genetics ; Nitriles/therapeutic use ; Prognosis ; Prostate-Specific Antigen ; Receptors, Androgen/genetics

المؤلفون: Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan., Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Basappa NS; Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Méndez-Vidal MJ; Department of Medical Oncology, Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain., Tjulandin S; Department of Clinical Pharmacology and Chemotherapy, N N Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, Russia., Hoon Park S; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Melichar B; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Hutson T; Department of Medical Oncology, Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA., Alemany C; Department of Hematology and Oncology, AdventHealth Cancer Institute, Orlando, FL, USA., McGregor B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Powles T; Department of Oncology, The Royal Free NHS Trust, London, England, UK; Department of Oncology, Barts Cancer Institute, Queen Mary Institute of London, London, UK., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany., Alekseev B; Department of Onco-urology, P A Hertsen Moscow Cancer Research Institute, Moscow, Russia., Rha SY; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Kopyltsov E; State Institution of Healthcare 'Regional Clinical Oncology Dispensary', Omsk, Russia., Kapoor A; Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., Alonso Gordoa T; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Goh JC; ICON Research, South Brisbane, QLD, Australia; Department of BioMedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia., Staehler M; Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany., Merchan JR; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Xie R; Biostatistics, Eisai, Nutley, NJ, USA., Perini RF; Clinical Research, Merck, Rahway, NJ, USA., Mody K; Clinical Research, Eisai, Nutley, NJ, USA., McKenzie J; Clinical Research, Eisai, Nutley, NJ, USA., Porta CG; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy.

المصدر: The Lancet. Oncology [Lancet Oncol] 2023 Mar; Vol. 24 (3), pp. 228-238.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell* , Kidney Neoplasms*, Female ; Humans ; Male ; Middle Aged ; Everolimus ; Follow-Up Studies ; Sunitinib